Doravirine vs Tenofovir alafenamide/emtricitabine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Tenofovir alafenamide/emtricitabine · Descovy

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Reliable signal

NCT02121795 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.

Next expected readout: January 2027 · NCT07349758 (registry estimate)

Reported efficacy

Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)

Result source: NCT02842086

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDoravirineTenofovir alafenamide/​emtricitabine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT042237780.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850

HIV-1 RNA below 50 copies/mL (week 48)

Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
Tenofovir alafenamide/​emtricitabine
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594

HIV-1 RNA 50 copies/mL or more (week 48)

Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
Tenofovir alafenamide/​emtricitabine
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246

CD4 count, change (week 48)

Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
Tenofovir alafenamide/​emtricitabine
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Doravirine: 13 of 13 rows · Tenofovir alafenamide/emtricitabine: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDoravirine
Rows use multiple source trials
Tenofovir alafenamide/​emtricitabine
Rows use multiple source trials
CD4
percent change · % of baseline
No placebo or comparator arm
-0.4% (n=43) @ 48wka,b
NCT03332095 · Phase 1/2 · combination
5.7% (n=35) @ 48wka,b
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
-1.1% (n=10) @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
-0.1% (n=48) @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
CD4+
absolute change · cells/uL
No placebo or comparator arm
80.1 cells/uL @ 48wkc,d
NCT03332095 · Phase 1/2 · combination
224 cells/uL @ 48wke,c,d
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 2 more doses
-66 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-179 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
CD4+
absolute change · percentage points
No placebo or comparator arm
4.49% (n=284) @ 96wkf,d,g,h
NCT04223778 · Phase 3 · registry result, not featured evidence
9.3% (n=50) @ 48wke,f,d,g,h
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 2 more doses
-0.6% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0.2% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
Hip BMD
percent change · % of baseline
Maintenance
0.6% (n=35) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mge,i,j,g
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-0.81% (n=40) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
-0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wki,j,g
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1 other source trial
1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Induction
-1.23 vs 0.03 placebo log @ 1wke,k,b,l
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
-1.23 vs -0.44 ISL log @ 1wk
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
-3.03 vs -3.15 DTG + F/TAF log @ 12wkk,b,l
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.1 log @ 48wka,b
NCT03332095 · Phase 1/2 · combination
-3.04 log @ 48wka,b
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA 0.5 log10 Decrease
responder rate · % of participants
Induction
85.7% (n=7) vs 0% (n=7) placebo @ 1wke,b,g,m
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
85.7% (n=7) vs 28.6% (n=7) ISL @ 1wk
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
60.7% (n=28) vs 0% (n=15) placebo @ 1.428571wke,b,g,m
NCT01967940 · Phase 3 · registry result, not featured evidence
show 1 more dose
58.3% (n=12) vs 0% (n=15) placebo @ 1.428571wk
NCT01967940 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
92.5% (n=40) @ 96wka,b,g
NCT03332095 · Phase 1/2 · combination
88.4% (n=242) @ 96wke,a,b,g
NCT01818596 · Phase 3
show 1 more dose
100% (n=6) @ 96wk
NCT01818596 · Phase 3
Lumbar Spine BMD
percent change · % of baseline
Maintenance
0.88% (n=35) vs 0.38% (n=40) INSTI+TAF/FTC @ 48wk100 mge,i,j,g
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.43% (n=42) vs 0.38% (n=40) INSTI+TAF/FTC @ 48wk100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wki,j,g
NCT02616783 · Phase 3 · registry result, not featured evidence
Dropout rate
24.2%100 mgn
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
11.4%F/TAF + 3rd Agento
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
23.5%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
20%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
5.1%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
12.6%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
4%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
1.9%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
4.4%
NCT04782180 · Phase 4 · registry result, not featured evidence
18.7%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
17.1%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
5.3%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
5.4%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
0%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
9.1%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.3%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
8%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
21.2%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
19.4%
NCT01565850 · Phase 2 · registry result, not featured evidence
3%
NCT03960645 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1.6%100 mgn
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
1.5%F/TAF + 3rd Agento
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
4.2%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
0.7%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
0.7%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
2.8%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
—Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—
NCT04782180 · Phase 4 · registry result, not featured evidence
1.2%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
2.7%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
—Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
—E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
1.9%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
0%
NCT01565850 · Phase 2 · registry result, not featured evidence
—
NCT03960645 · Phase 1 · registry result, not featured evidence
Serious AEs
11.7%100 mgn
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—F/TAF + 3rd Agento
NCT02121795 · Phase 3 · combination
show 52 more results
8.7%F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
6.1%Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
9.7%Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
—F/TAF
NCT02469246 · Phase 3
19.6%F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
0%Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
0%Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
—E/C/F/TAF
NCT01797445 · Phase 3
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
—E/C/F/TAF
NCT01815736 · Phase 3
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
22.7%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
16.7%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
20%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
13.5%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
3.7%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%
NCT04782180 · Phase 4 · registry result, not featured evidence
20%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
14%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
4.5%Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
9.5%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
16.2%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
10.7%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
10.8%Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
16.2%HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
0%HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
4.8%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
10.1%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
6%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
7.7%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.9%
NCT01565850 · Phase 2 · registry result, not featured evidence
18.2%
NCT03960645 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
100 mgn
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
o
upper respiratory tract infection 16.2%
diarrhoea 13.2%
nasopharyngitis 12.9%
NCT02121795 · Phase 3 · combination
show 45 more results
nasopharyngitis 12.1%
back pain 9.1%
syphilis 9.1%
NCT02121795 · Phase 3
onychomycosis 9.7%
sinusitis 9.7%
arthralgia 6.5%
NCT02121795 · Phase 3
nasopharyngitis 20.4%
upper respiratory tract infection 12.9%
cough 12.1%
NCT02469246 · Phase 3
nasopharyngitis 20%
renal colic 20%
rhinitis 20%
NCT02469246 · Phase 3
spinal pain 16.7%
arthralgia 0%
back pain 0%
NCT02469246 · Phase 3
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3
upper respiratory tract infection 16.1%
bronchitis 15.3%
arthralgia 14%
NCT01818596 · Phase 3
hyperlipidaemia 33.3%
pain in extremity 33.3%
anogenital warts 16.7%
NCT01818596 · Phase 3
upper respiratory tract infection 40%
respiratory tract infection 38%
nausea 30%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 26.9%
vomiting 25%
respiratory tract infection 21.2%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 51.9%
cough 33.3%
nasopharyngitis 18.5%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
arthralgia 9%
diarrhoea 4.5%
headache 4.5%
NCT02605954 · Phase 3 · registry result, not featured evidence
diarrhoea 10.4%
headache 8.2%
vitamin d deficiency 7.1%
NCT02605954 · Phase 3 · registry result, not featured evidence
urinary tract infection 13.5%
upper respiratory tract infection 12.2%
arthralgia 9.5%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
cough 13.5%
headache 10.8%
nausea 8.1%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
hyperbilirubinaemia 3.6% (placebo 0%)
influenza 3.6% (placebo 0%)
jaundice 3.6% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
nausea 16.7% (placebo 0%)
arthralgia 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 29.7% (placebo 0%)
malaria 13.5% (placebo 0%)
headache 10.8% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 23%
nasopharyngitis 12.2%
diarrhoea 10.8%
NCT02071082 · Phase 3 · registry result, not featured evidence
dental caries 33.3%
diarrhoea 33.3%
herpes zoster 33.3%
NCT02071082 · Phase 3 · registry result, not featured evidence
acute sinusitis 19%
bronchitis 14.3%
sinusitis 14.3%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
back pain 12.4%
upper respiratory tract infection 11.2%
bronchitis 6.7%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
cough 24%
upper respiratory tract infection 22%
vomiting 16%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 60%
cough 50%
nasal obstruction 30%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 21.4%
upper respiratory tract infection 15.5%
fatigue 13.6%
NCT01565850 · Phase 2 · registry result, not featured evidence
back pain 12.1%
gestational diabetes 12.1%
anaemia 9.1%
NCT03960645 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 1/2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTrial phases differ: Phase 1/2 versus Phase 2/3.
  4. dPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 3 versus Phase 2/3.
  7. gTreatment context has not been resolved for both arms.
  8. hAssessment timepoints differ: 96 weeks versus 48 weeks.
  9. iTrial phases differ: Phase 4 versus Phase 3.
  10. jPopulation context differs: registered conditions differ.
  11. kTrial phases differ: Phase 3 versus Phase 2.
  12. lAssessment timepoints differ: 1 weeks versus 12 weeks.
  13. mAssessment timepoints differ: 1 weeks versus 1.428571 weeks.
  14. nPopulation comparability has not been reviewed for 24 of these studies.
  15. oPopulation comparability has not been reviewed for 47 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Doravirine

LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Total Cholesterol Change mg/dL -1.37 mg/dL @ 48wk100 mg
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02275780 · Phase 3 · combination
Triglyceride Change mg/dL -3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HIV-1 RNA Less Than 40 Copies 83.3% (n=383) vs 79.1% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · combination
show 3 more results
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
83.8% (n=364) vs 79.7% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Triglycerides -12.4% (n=333) vs 22.01% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
HDL-C 1.86% (n=333) vs 8.51% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3

+ 30 further endpoints in the CSV export.

Tenofovir alafenamide/emtricitabine

HIV-1 RNA Less Than 20 Copies 91.6% (n=333) vs 90.9% (n=330) FTC/TDF @ 48wk
responder rate · % of participants
NCT02121795 · Phase 3 · combination
show 6 more results
83.5% (n=333) vs 86.1% (n=330) FTC/TDF @ 96wk
NCT02121795 · Phase 3 · combination
85.7% (n=280) vs 87.3% (n=276) ABC/3TC @ 48wk
NCT02469246 · Phase 3
80.4% (n=280) vs 86.2% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3
90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less 400 94% (n=50) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 9 more results
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA -3.25 copies/mL @ 24wk
absolute change · copies/mL
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 1 more result
-3.26 copies/mL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
CD4+ 265 vs 35 GEN cells/uL
absolute change · cells/uL
Extension (open-label)
NCT01705574 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies Per 94.5% (n=109) vs 100% (n=55) Stay on Baseline Regimen @ 24wk
responder rate · % of participants
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
93.6% (n=109) vs 94.5% (n=55) Stay on Baseline Regimen @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
HCV SVR 98.6% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
95.8% (n=72) @ 12wk
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
98.6% (n=72) @ 4wk
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
98.6% (n=72) @ 4wk
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure Rate 50 1.4% (n=74) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
1.4% (n=74) @ 24wk
NCT02707601 · Phase 3 · registry result, not featured evidence · combination

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Tenofovir alafenamide/emtricitabine's landscape